Thermo Fisher to Acquire Clario for Up to $9.4 Billion

Thermo Fisher Scientific has announced its acquisition of Clario, a clinical trial data company, for a total consideration of up to $9.4 billion. The agreement includes an upfront cash payment of approximately $8.88 billion, followed by a scheduled payment of $125 million in January 2027. Furthermore, Clario is eligible for up to $400 million in earn-out payments, contingent upon its performance during 2026 and 2027. Thermo Fisher Scientific's Chairman, President, and CEO Marc Casper emphasized the strategic benefits of the acquisition, stating that Clario's "differentiated technology and data intelligence solutions" will facilitate "faster, more informed drug development." Puneet Souda, an analyst at Leerink Partners, noted that the acquisition enhances Thermo Fisher's presence in the clinical development sector, a market he characterized as exhibiting "steadily growing and attractive" characteristics.